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MaOBJECTIVES The aim of this study was to assess the feasibility of hybrid coronary revascularization (HCR) in
patients with multivessel coronary artery disease (MVCAD) referred for standard coronary artery bypass grafting
(CABG).
BACKGROUND Conventional CABG is still the treatment of choice in patients with MVCAD. However, the limitations of
standard CABG and the unsatisfactory long-term patency of saphenous grafts are commonly known.
METHODS A total of 200 patients with MVCAD involving the left anterior descending artery (LAD) and a critical
(>70%) lesion in at least 1 major epicardial vessel (except the LAD) amenable to both PCI and CABG and referred for
conventional surgical revascularization were randomly assigned to undergo HCR or CABG (in a 1:1 ratio). The primary
endpoint was the evaluation of the safety of HCR. The feasibility was deﬁned by the percent of patients with a
complete HCR procedure and the percent of patients with conversions to standard CABG. The occurrence of major
adverse cardiac events such as death, myocardial infarction, stroke, repeated revascularization, and major bleeding within
the 12-month period after randomization was also assessed.
RESULTS Most of the pre-procedural characteristics were similar in the 2 groups. Of the patients in the hybrid group,
93.9% had complete HCR and 6.1% patients were converted to standard CABG. At 12 months, the rates of death
(2.0% vs. 2.9 %, p ¼ NS), myocardial infarction (6.1% vs. 3.9%, p ¼ NS), major bleeding (2% vs. 2%, p ¼ NS), and repeat
revascularization (2% vs. 0%, p ¼ NS) were similar in the 2 groups. In both groups, no cerebrovascular incidents were
observed.
CONCLUSIONS HCR is feasible in select patients with MVCAD referred for conventional CABG. (Safety and Efﬁcacy
Study of Hybrid Revascularization in Multivessel Coronary Artery Disease [POL-MIDES]; NCT01035567) (J Am Coll
Cardiol Intv 2014;7:1277–83) © 2014 by the American College of Cardiology Foundation.C onventional coronary artery bypass grafting(CABG) is still the current, evidence-based,gold standard treatment of patients with
multivessel coronary artery disease (MVCAD) (1,2).
The most advantageous part of CABG is the insertion
of the left internal mammary artery (LIMA) graft in
the left anterior descending artery (LAD) as it is asso-
ciated with signiﬁcantly reduced risk of death,
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ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery bypass
grafting
DES = drug-eluting stent(s)
HCR = hybrid coronary
revascularization
HPS = HYBRID patency score
LAD = left anterior descending
artery
LIMA = left internal mammary
artery
MIDCAB = minimally invasive
direct coronary artery bypass
MVCAD = multivessel coronary
artery disease
MVD = multivessel disease
PCI = percutaneous coronary
intervention
SVG = saphenous vein graft
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1278provides a promising alternative to SVG.
Thus, taking into account similar patency
rates of DES and SVG and the superiority of
the LIMA-LAD, the fundamental basis for
the hybrid coronary revascularization (HCR)
strategy was set, consisting of minimally
invasive direct coronary artery bypass (MID-
CAB) LIMA-LAD grafting using endoscopic
LIMA harvesting (MIDCAB/endoscopic atrau-
matic coronary artery bypass) and catheter-
based techniques with implantation of DESs
in non-LAD vessels. Because of the lack of
data from prospective, randomized trials
comparing HCR with standard surgical revas-
cularization in patients with MVCAD, the
POL-MIDES (HYBRID) (Safety and Efﬁcacy
Study of Hybrid Revascularization in Multi-
vessel Coronary Artery Disease) was de-
signed as the ﬁrst one to assess feasibility
of such an approach.SEE PAGE 1284METHODS
STUDY DESIGN. The study design was described
previously (10). Brieﬂy, the POL-MIDES (HYBRID) is
a prospective, single-center, randomized, open-
label, parallel pilot study. The authors designed the
study in collaboration with the Ministry of Science
and Higher Education of Poland. A statistician per-
formed the analyses of the data. The authors wrote
the paper and conﬁrm the completeness and accu-
racy of data gathering and analysis. The study pro-
tocol was approved by the local ethics committee
and complies with the Declaration of Helsinki.
Written informed consent was obtained from all
study participants.
The Steering Committee of the POL-MIDES
(HYBRID) comprising independent, university-based
researchers (Medical University of Silesia, Katowice,
Poland) with methodological and clinical experience
was responsible for the assessment of all clinical
events, data collection, monitoring, ﬁnal analyses, as
well as the preparation and publication of the man-
uscripts reporting the study results.
SELECTION AND RANDOMIZATION OF PATIENTS.
All consecutive patients with angiographically
conﬁrmed MVD involving the LAD and critical (>70%)
lesion in at least 1 (apart from the LAD) major
epicardial vessel amenable to both PCI and CABG and
referred for conventional surgical revascularization
were screened by the local heart team (at least 1interventional cardiologist with a cardiothoracic sur-
geon). The heart team checked all the inclusion/
exclusion criteria and the eligibility to perform CABG
and PCI in all study participants. It was determined
that equivalent anatomic revascularization could be
achieved in patients with either CABG or PCI using
Xience everolimus-eluting stents (Abbott Vascular,
Abbott Park, Illinois) were randomly assigned to un-
dergo 1 of the 2 treatment options. Randomization
was conducted in a 1:1 ratio. Figure 1 shows the study
ﬂow chart.
PRIMARY ENDPOINT. The primary endpoint was the
evaluation of the feasibility of HCR. The feasibility
endpoint was deﬁned by the percent of patients with
a complete hybrid procedure according to study pro-
tocol and the percent of conversions to standard
CABG. Occurrence of major adverse cardiac events
such as death, myocardial infarction, stroke, repeat
revascularization, major bleeding throughout the 12-
month period after randomization was also
assessed. An independent clinical events committee
(including cardiologists, cardiac surgeons, and a
neurologist) adjudicated all primary clinical end-
points, staged procedures, and cases of reopening of
the sternal incision.
SECONDARY ENDPOINTS. The secondary endpoints
were post-procedure and follow-up angiographic
measurements (12 months after randomization) of
the patency of the grafts and restenosis in revascu-
larized segments, assessment of quality of life of
study participants according to Short Form-36
Health Survey version 2 (1 and 6 months after the
procedure), and cost-effectiveness deﬁned as the
cost of the revascularization procedure and of hos-
pitalizations in both groups; the latter 2 points are
the subject of a separate analysis and are not pre-
sented here.
REVASCULARIZATION AND PHARMACOLOGICAL
TREATMENT. In both arms of the study, patients
were treated with the intention of achieving complete
revascularization of all vessels at least 2.0 mm in
diameter with stenosis of $50%, as identiﬁed by
the interventional cardiologist and cardiac surgeon.
The surgical technique for CABG, the approaches
used for HCR stages, and the post-procedure medi-
cation regimen were chosen according to local clinical
practice and European Society of Cardiology guide-
lines. In patients in the HCR arm who underwent PCI,
dual-antiplatelet therapy with aspirin and clopidogrel
was recommended for at least 12 months after stent
implantation. For CABG procedure, arterial revascu-
larization was encouraged. Aspirin was prescribed
indeﬁnitely for all patients who underwent
FIGURE 1 Study Flow Chart in the HYBRID Trial
From screened eligible patients to intent-to-treat analysis. CABG ¼ coronary artery bypass
grafting; DES ¼ drug-eluting stent; EACAB ¼ endoscopic atraumatic coronary artery
bypass; LIMA-LAD ¼ left internal mammary artery–left anterior descending artery;
MIDCAB ¼ minimally invasive direct coronary artery bypass; MVD ¼ multivessel disease;
OPCAB ¼ off-pump coronary artery bypass grafting; PCI ¼ percutaneous coronary
intervention.
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1279randomization. The standard of post-intervention
care was recommended.
Follow-up assessments were carried out at hospital
discharge and at 3, 6, and 9 months after the revascu-
larization procedure. After 12 months, patients were
asked to undergo control angiography.
STATISTICAL ANALYSIS. The continuous variables
are presented as the mean  SD. The categorical
variables are presented as percents. To test for dif-
ferences between the CABG and HCR groups, the
Student t and the chi-square tests were used. Major
adverse cardiac events were analyzed using the
Kaplan-Meier method, the log-rank test, and an
observed difference with a 95% conﬁdence interval
was calculated. All analyses were on the basis of the
intention-to-treat principle. A 2-sided p value <0.05
was considered statistically signiﬁcant. Statistical
tests were performed with STATISTICA 10PL software
(StatSoft, Inc., Tulsa, Oklahoma).
RESULTS
From November 2009 to July 2012, 200 patients
with conﬁrmed MVD and referred for conventional
CABG were randomized to HCR (n ¼ 98) or CABG
(n ¼ 102) Demographic, clinical, angiographic, and
procedural characteristics were well balanced and
similar in both treatment groups (Table 1). Com-
pared with the CABG group, patients in the HCR
group had slightly lower body mass index (HCR,
28.2 vs. CABG, 29.1; p ¼ 0.07). Overall, w4 clinically
signiﬁcant coronary lesions were treated per patient
(mean, 4.0 for HCR vs. 3.7 for CABG; p ¼ 0.16). More
than half of the study patients had 3-vessel disease
(54.1% in HCR vs. 53.9% in CABG; p ¼ 0.1). Despite
the fact that signiﬁcant left main artery disease and
the presence of >1 chronic total occlusion were the
exclusion criteria in the trial, a mean SYNTAX score
was 23.4 in the HCR group and 22.8 in the CABG
group (p ¼ 0.48) (Table 1). Planned revascularization
procedures were performed in 93.9% in the HCR
group and in all patients in the CABG group and. In
the HCR group, a mean of 2.3 stents per patient
were placed, whereas in the CABG group, 85.0% of
patients were operated on off-pump, using the off-
pump CABG technique. Complete arterial revascu-
larization was achieved in 24.5% of the patients,
and an mean of 2.7 conduits were implanted.
As expected, the MIDCAB procedure was signiﬁ-
cantly shorter than CABG. The mean time from MID-
CAB to PCI was 21 h. Together with DES implantation,
the LIMA-LAD was assessed. In 2 patients, it was
found to be suboptimal and resulted in subsequent
PCI of the LAD in 1, and repeat MIDCAB in a secondpatient. The HCR group included 6 patients who were
converted to sternotomy (intention-to-treat HCR).
These patients did not undergo PCI, as all coronary
lesions were addressed with CABG. There were 2 pa-
tients who had the ﬁrst stage of the HRC performed
(MIDCAB) but failed PCI (2%). These patients under-
went PCI with rotational atherectomy as an auxiliary
method at a later time (outside of time planned in the
study protocol).
Clinical events occurring during hospitalization and
the primary endpoint and its components are pre-
sented in Table 2. Therewere no signiﬁcant differences
in in-hospital outcome. In 1 patient in the HYBRID
group, acute renal failure developed requiring dial-
ysis. The incidence of perioperative myocardial
infarction and length of hospitalization were similar.
The cumulative occurrence of major adverse
cardiac events was 10.2% and 7.8% for HCR and
TABLE 1 Baseline Characteristics of the Patients, According to the
Study Groups*
CABG
(n ¼ 102)
HCR
(n ¼ 98) p Value
Age at randomization, yrs 63.9  8.4 63.1  8.2 0.43
Male, % 71.6 79.6 0.19
Body mass index, kg/m2 29.1  4.2 28.2  3.3 0.07
Medically treated diabetes, %† 30.4 25.5 0.44
Current smoker, % 35.3 30.6 0.48
Previous myocardial infarction, % 57.8 53.1 0.49
Previous stroke, % 4.9 4.1 0.95
Previous transient ischemic attack, % 2.9 1.0 0.64
Hypertension, % 82.4 88.8 0.20
Carotid artery disease, % 11.8 9.2 0.55
Hyperlipidemia, % 59.8 56.1 0.60
Angina, %
Stable 83.2 85.7 0.64
Unstable 16.7 14.3 0.64
Ejection fraction, % 50.7  7.0 49.8  6.3 0.37
EuroSCORE value 3.4  2.0 3.1  2.1 0.23
SYNTAX score 22.8  5.3 23.4  6.3 0.48
No. of lesions 3.7  1.2 4.0  1.4 0.16
Total occlusion, %
Left anterior descending artery 29.4 22.4 0.44
Right coronary artery 6.9 6.1 0.83
Ramus circumﬂex artery 10.8 8.2 0.28
No. of grafts 2.6  0.7 1.2  0.7 NA
No. of arterial grafts 1.6  0.9 1.1  0.1 NA
Complete arterial revascularization, % 24.5 — NA
Post-procedural LIMA patency, % — 97.8 NA
No. of stents used — 2.3  1.0 NA
Total drainage, ml 1,168  486 1,018  730 0.1
Time MIDCAB to PCI, h — 21.0  5.7 NA
In-hospital stay, days 8.9  5.6 8.8  4.3 0.88
Complete revascularization, % 78.4 78.6 0.84
Values are mean  SD or %. *Values are given for the intention-to-treat population. †Medically
treated diabetes was deﬁned as diabetes for which the patient was receiving oral hypoglycemic
agents or insulin at the time of enrollment.
CABG ¼ coronary-artery bypass grafting; HCR ¼ hybrid coronary revascularization; LIMA ¼ left
internal mammary artery; MIDCAB ¼ minimally invasive coronary artery bypass; NA ¼ not
applicable; PCI ¼ percutaneous coronary intervention.
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1280CABG, respectively (p ¼ 0.54 by the log-rank test)
with an observed difference of 2.4% (95% conﬁdence
interval: 5.6% to 10.3%) (Figure 2). The secon-
dary endpoint, 12-month follow-up angiographic
measurements of the patency of grafts and restenosis
in revascularized segments, is shown in Table 3.
Angiographic follow-up was performed in 85% and
81% of patients in HCR and CABG groups, respectively
(p ¼ 0.41). The patency of arterial grafts to the LAD
was substantial at 94% and 93% (HCR vs. CABG).
Although 1 LIMA conduit was signiﬁcantly narrowed
in the HCR group, 5 grafts were found narrowed in the
CABG group; 79% of the remaining conduits were free
of occlusion and obstruction. In the HCR group, 5.1%
stent occlusion rate and 7.5% signiﬁcant in-stent
restenosis was discovered. The HYBRID patencyscore (HPS) was created to compare the long-term
effect of hybrid revascularization with long-term
patency of the grafts after standard CABG deﬁned as
grafted or stented arteries free of stenosis and/or
occlusions with the total number of grafted and
stented arteries ratio, which was signiﬁcantly higher
in the HCR group (90% vs. 81%, p ¼ 0.01).
DISCUSSION
The primary aim of the study was to evaluate the
feasibility of an integrated, 2-stage HCR procedure in
patients with MVD referred for standard, open-chest
CABG. The POL-MIDES (HYBRID), the ﬁrst random-
ized study for HCR is unique from various perspec-
tives. First, it proved that HCR is feasible in a select
population of patients with MVCAD. Second, MIDCAB
with LIMA to LAD as a ﬁrst-stage procedure in HCR
patients was not associated with a signiﬁcant increase
in adverse events.
Our study has shown HCR to be safe in patients
with MVCAD, with surgical treatment preceding
endovascular. However, in 6 patients (6.1%), con-
version to full sternotomy had to be performed. In
4 patients, the conversion was not emergent, but
rather planned as the result of either the inability to
perform single lung ventilation due to severe chronic
obstructive pulmonary disease or the inability to
visualize the LIMA due to pleural adhesions. In both
cases, there were only port incisions on patients’
chests, not thoracotomy incisions. In 2 other patients,
endoscopic LIMA harvesting was successful, but the
LAD could not be identiﬁed once thoracotomy was
performed. In 1 patient, there was a signiﬁcant
muscular bridge covering the LAD, whereas in the
second patient, there was a large amount of fatty
tissue covering the entire myocardium. In both pa-
tients, full sternotomy provided better visualization,
enabling complete surgical revascularization.
In the last 2 patients, emergent conversion was
required. Hemodynamic instability that occurred
shortly after LAD occlusion and preparation for
intraluminar coronary shunt placement followed by
ventricular ﬁbrillation was the main reason for MID-
CAB to CABG emergent conversion in the ﬁrst patient.
In the second patient, signiﬁcant bleeding that was
difﬁcult to manage by endoscopic techniques led to
prompt sternotomy. Similar reasons for emergent and
planned sternotomy conversions were reported
in patients with single-vessel diseases undergoing
MIDCAB/endoscopic atraumatic coronary artery
bypass (11). Most importantly, the above-mentioned
events were easily managed with median sternot-
omy, which did not inﬂuence early or late outcome. It
TABLE 2 Clinical Endpoints Occurring in the Hospital or After
Discharge According to Study Group*
CABG HCR p Value
In-hospital outcomes, %
Blood transfusion 26.5 19.4 0.23
Perioperative myocardial infarction 3.9 5.1 0.69
Renal failure 0 1.0 0.98
Stroke 0 0 NA
Death 0 0 NA
Primary endpoint
Feasibility
Patients with complete hybrid procedure, % — 93.9 NA
Conversion to standard CABG, %† — 6.1 NA
Safety
Major adverse cardiac events at 12 mo after
randomization
Death, % 2.9 2.0 0.1
Myocardial infarction, %‡ 3.9 6.1 NS
Stroke, % 0 0 NA
Target vessel revascularization, % 0 2.0 NS
Major bleeding, % 2.0 2.0 NS
*Values are given for the intention-to-treat population. †Reasons for converting:
Left anterior descending artery not visible through mini-thoracotomy incision
in 2 patients. Hemodynamically unstable when preparing left anterior descending
artery for grafting, recurrent ventricular tachycardia, emergency conversion to full
sternotomy in 1 patient. Left internal mammary artery damaged during endoscopic
harvesting in 1 patient. Solid adhesions in the left thoracic cavity, endoscopicor direct
left internal mammary artery harvesting impossible in 1 patient. Lack of tolerance of
single lung ventilation in 1 patient. ‡Includes perioperative myocardial infarction.
Abbreviations as in Table 1.
TABLE 3 Secondary Endpoint: 12-Month Follow-Up Angiographic
Measurements as Patency of Grafts and Restenosis in
Revascularized Segments*
CABG HCR p Value
Follow-up duration, months 12.6  0.4 12.9  0.4
Angiographic follow-up, % 81 85 0.41
LAD arterial graft patency, % 93† 94‡ 0.74
LAD arterial graft stenosis $70%, % 5 1 0.36
Other grafts patency, %§ 79 — NA
Other grafts stenosis, % 2 — NA
In-stent occlusions, % — 5.1 NA
In-stent restenosis $50%, % 7.5 NA
HYBRID patency score, %k 81 90 0.01
*Values are given for the intention-to-treat population. †Seventy left internal
mammary artery grafts and 13 right internal mammary artery grafts. ‡Aortic-LAD
graft in 1 patient. §Saphenous vein grafts and non-LAD arterial grafts. kHYBRID
patency score: free of stenosis/occlusions grafted or ratio of stented arteries to
total number of grafted and stented arteries.
LAD ¼ left anterior descending artery; other abbreviations as in Table 1.
FIGURE 2 Kaplan-Meier Estimates of the Composite Primary Feasibility Endpoint
Percentage of patients free from MACE within a 12-month follow-up. CABG ¼ coronary
artery bypass grafting; MACE ¼ major adverse cardiac event(s).
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1281is noteworthy that the vast majority of patients in the
surgical arm underwent off-pump CABG. Although
the surgical technique was left to patients’ prefer-
ence, we did not observe signiﬁcant differences be-
tween patients operated on using either method.
There were no off-pump CABG to CABG intra-
operative conversions.
As the population of the patients with MVD
referred for CABG is growing older with greater
comorbidities, less invasive and hazardous tech-
niques should be explored. The intention of the cor-
onary artery hybrid revascularization is to combine
the most valuable asset of the standard CABG (i.e.,
excellent long-term durability of the LIMA-to-LAD
graft) with the advantages of PCI (i.e., low rate of
stent restenosis and durability of DES superior to SVG
patency). Several small retrospective studies have
demonstrated that a HCR strategy is safe with low
mortality rates (0% to 2%) and event-free survival
rates of 83% to 92% at 6 to 12 months of follow-up.
The few series that compared the outcomes of HCR
with the standard CABG reported similar outcomes at
30 days and 6 months (12–14). The results of these
studies are consistent with our ﬁndings. To the best
of our knowledge, to date, no randomized, controlled
trial involving HCR has been published. Therefore,the current practice guidelines recommend HCR as
reasonable only if CABG or PCI of the LAD are con-
traindicated due to severe clinical and/or anatomic
reasons or recommend as worthy of consideration
instead of CABG or multiple PCIs to improve the
overall risk-beneﬁt ratio of these procedures (2).
In the SYNTAX trial, more patients in the CABG
group than in the PCI group declined to participate
after providing consent, mostly due to the greater
invasiveness of CABG (15). Despite this growing
awareness of patients about the possibility of mini-
mally invasive revascularization, the hybrid approach
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1282has not been widely accepted. This may be explained
by a number of practical concerns: the need for close
cooperation of CABG and PCI operators, the logistic
concerns of timing and sequencing of the procedure
stages, use of aggressive antiplatelet/antithrombotic
therapy during PCI that might complicate the surgical
part of the HCR procedure with bleeding and a high
risk of the surgical stage of the HCR, especially in
unstable patients with MVD and critical stenoses in
non-LAD segments. A small incision and difﬁcult
surgical (endoscopic) technique used to harvest LIMA
remains a barrier for widespread acceptance. There-
fore, we believe that this study provides unique and
vital information to dispel doubts regarding HCR: ﬁrst,
the fact that mean enrollment time for 1 patient was
4.8 days proves that the heart team was well orga-
nized, effective, and bias free; second, a staged HCR
procedure with PCI performed within ﬁrst 24 h after
the surgical portion is feasible. Moreover, veriﬁcation
of the LIMA-to-LAD conduit patency before PCI of
other vessels adds to periprocedural safety despite the
routine use of the transit time ﬂow meter. The risk of
perioperative bleeding that would occur if surgery
were performed after PCI in a patient already started
on dual-antiplatelet therapy is reduced. Third, we
found that, despite the fact the patients received a full
dose of clopidogrel after the surgical part of the HCR,
blood loss and transfusion requirements were slightly
reduced in the HCR group compared with the CABG
group. These ﬁndings are corroborated by other
reports (16), and in particular, the POL-MIDES
(HYBRID) study results suggest that clopidogrel pre-
treatment is safe and potentially beneﬁcial. Finally,
the periprocedural myocardial infarction rate,although insigniﬁcantly higher in the HCR group, was
low and without any severe consequences. The HPS
was introduced to overcome limitations of classic
head-to-head angiographic ﬁndings of the 2 different
revascularization methods. The HPS consists of the
ratio of the grafted or stented arteries free of stenosis/
occlusion to all the grafted/stented arteries. In our
analysis, we found that the HPS was signiﬁcantly
higher in the POLMIDES (HYBRID) group.
Easily calculated, comparable, and consistent, the
HPS is a reliable tool to assess the angiographic
effectiveness of HCR.
STUDY LIMITATIONS. Because of the pilot nature
of the POL-MIDES (HYBRID) trial, although it was able
to prove feasibility, it was not powered to detect
difference in mortality. The second limitation is that
the 12-month follow-up period may not be sufﬁcient
to reﬂect the true long-term effect of CABG com-
pared with HCR when taking into consideration
major adverse cardiac events. Investigators of the
POL-MIDES (HYBRID) trial continue to monitor all
study participants so that similar SYNTAX time points
can be reported.
CONCLUSIONS
The results of our trial show that HCR is feasible in
select patients with MVCAD referred for conventional
CABG.
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